The Massachusetts Prostate Cancer Coalition (MPCC) educates, connects, and supports men-at-risk, newly diagnosed individuals, survivors, and their families. It also connects organizations and professionals in Massachusetts that seek to conquer and cure prostate cancer.
Our Vision: Educate | Inform | Advocate
Five Facts about Prostate Cancer
1PrevalenceProstate cancer is the most common (non-skin) cancer in American men.
2Prostate cancer effects 1 in 7 men.1 in 7 men will be diagnosed with prostate cancer during their lifetime. This year in Massachusetts another 4,762 new cases will be diagnosed.
3Second leading cause of cancer death in men.Prostate cancer is the second leading cause of cancer death in American men, behind only lung cancer. In Massachusetts, 614 men will die from prostate cancer this year.
4Prostate cancer top risk factors.
African-American men are twice as likely to die of prostate cancer as white men. Asian-Americans and Hispanic/Latinos have lower rates of prostate cancer than non-Hispanic white men.
Prostate cancer occurs mainly in older men. About 6 cases in 10 are diagnosed in men aged 65 or older, and it is rare before age 40. The average age at the time of diagnosis is about 66.
5This year 27,540 men will die of prostate cancer.
Yet, most men diagnosed with prostate cancer will not die from it. In fact, more than 2.9 million men in the United States who have been diagnosed with prostate cancer at some point are still alive today.
Statistics from The American Cancer Society 2015
We need your support! Become a Member or Donate to MPCC today.
As a national leader in oncology advancement and as the largest integrated healthcare system in the nation, the Department of Veterans Affairs (VA) today announced an important and substantial partnership with the Prostate Cancer Foundation (PCF) to prevent, screen and promote research to speed the development of treatments and cures for prostate cancer among Veterans… read more →
Newswise — An international group of researchers report success in mice of a method of using positron emission tomography (PET) scans to track, in real time, an antibody targeting a hormone receptor pathway specifically involved in prostate cancer. This androgen receptor pathway drives development and progression of the vast majority of prostate cancers. Read more read more →